Sanwa Kagaku Kenkyusho Co., Ltd.

Ube Industries, Inc.

Kaori Taniko

Takahito Jomori

Noriaki Kato

Hiroshi Nagano

Tomio Kimura

Motohisa Shimizu

Yasunori Tsuzaki

Ryo Iwamura

Hiroyuki Setoguchi

Satoko Harada

Morio Okabe

Toru Izuchi

Daisuke Kurumazuka

Toshiyuki Miyazawa

Hiroto Akaza

Yuuki Imura

Tatsuroh Kaneko

The object of the present invention is to provide a compound having an antagonistic action against &#x3bc;-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof:   

3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose

A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, Rand Rconcurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or Rand R, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro -2',5&#x2032;-dioxospiro chroman-4,4&#x2032;-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.

Prophylactic or therapeutic agent for diabetic maculopathy

A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, Rand Rconcurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or Rand R, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2',5&#x2032;-dioxospiro[chroman-4,4&#x2032;-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.

Growing community of inventors

Nagoya, Japan

Kaori Taniko